Monitoring of Breast Neoadjuvant Therapy by Thermo- and Photo- Acoustic Tomograph

通过热声和光声断层扫描监测乳腺新辅助治疗

基本信息

  • 批准号:
    8055443
  • 负责人:
  • 金额:
    $ 57.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-01 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We propose to develop high-resolution microwave-induced thermoacoustic tomography (TAT) and laser-induced photoacoustic tomography (PAT) by adapting a clinical ultrasound imaging system. These three compatible imaging modalities share the same ultrasound detection system and provide complementary contrasts. The long-term goal is to provide a clinical tool for the early functional monitoring of breast neoadjuvant therapy (chemo- or hormone therapy). Many breast cancer patients receive neoadjuvant treatment to reduce tumor size and enable breast conserving therapy that would otherwise have not been possible. A sensitive method of detecting response to therapy might allow earlier adjustments in treatment, and thus, result in better outcomes. Furthermore, if drug choices are not resulting in response, prompt and early changes in drug regimens will alleviate some of the unnecessary morbidity that patients suffer during treatment while awaiting response to therapy. TAT/PAT is based on the generation of thermoacoustic/photoacoustic waves by the safe deposition of short-pulsed electromagnetic energy into the breast. Each microwave/laser pulse causes a rapid temperature rise on the order of 10 millidegrees. The ultrasonic emission due to thermoelastic expansion is detected with an array of ultrasonic transducers and then used to reconstruct an image. TAT and PAT are designed to overcome the poor spatial resolution of pure microwave and pure optical imaging yet to retain the high contrasts. In terms of spatial resolution, pure microwave imaging suffers from strong diffraction due to long microwave wavelength, whereas pure optical imaging suffers from strong optical scattering in tissue. Ultrasonic waves can propagate in tissue with relatively low scattering and can therefore provide good spatial resolution. The applicants have demonstrated speckle-free images at high resolution (as low as 0.5 mm). We hypothesize that the combined contrasts from TAT and PAT as well as ultrasonography can accurately predict breast neoadjuvant therapeutic response. TAT measures dominantly water/sodium contrast, whereas PAT measures blood volume and blood oxygenation contrasts. The specific aims are as follows: 1. Development of the TAT/PAT breast imaging system. 2. Adaptation of a Philips clinical ultrasound imaging system. 3. Phantom study: Validate the proposed imaging system with tissue phantoms. 4. In vivo study: First, image a small number of human breasts to fine tune the imaging system. Second, image human breasts and perform statistical analysis retrospectively. Third, image human breasts and validate the imaging system prospectively. PUBLIC HEALTH RELEVANCE: Imaging technologies have enabled numerous discoveries in biomedicine and provided early diagnosis of disease. Functional imaging that detects not only tissue structure but also tissue function will make even greater impact in biomedicine. The proposed thermoacoustic and photoacoustic imaging technologies can potentially provide a clinical tool for the early functional monitoring of breast neoadjuvant therapy (chemo- or hormone therapy).
描述(由申请人提供):我们建议通过采用临床超声成像系统来开发高分辨率微波诱导热声断层扫描(TAT)和激光诱导光声断层扫描(PAT)。这三种兼容的成像方式共享相同的超声检测系统,并提供互补的对比。长期目标是为乳房新辅助治疗(化疗或激素治疗)的早期功能监测提供临床工具。许多乳腺癌患者接受新的辅助治疗,以缩小肿瘤大小,并实现保乳治疗,否则是不可能的。一种检测治疗反应的灵敏方法可能会使治疗更早调整,从而产生更好的结果。此外,如果药物选择没有产生反应,及时和及早改变药物方案将减轻患者在等待治疗反应期间在治疗期间遭受的一些不必要的发病率。TAT/PAT的基础是通过将短脉冲电磁能量安全地沉积到乳房中来产生热声/光声波。每一个微波/激光脉冲都会引起大约10毫度的快速升温。利用一组超声换能器检测由于热弹性膨胀而产生的超声波发射,然后用于重建图像。TAT和PAT旨在克服纯微波和纯光学成像的低空间分辨率,但仍不能保持高对比度。在空间分辨率方面,纯微波成像由于微波波长较长而受到强衍射的影响,而纯光学成像则受到组织中强烈的光学散射的影响。超声波可以以相对较低的散射在组织中传播,因此可以提供良好的空间分辨率。申请者展示了高分辨率(低至0.5 mm)的无斑点图像。我们假设,TAT和PAT的联合对比以及超声检查可以准确地预测乳房新辅助治疗的反应。TAT主要测量水/钠对比,而PAT测量血容量和血氧对比。具体目标如下:1.TAT/PAT乳腺成像系统的研制。2.飞利浦临床超声成像系统的改装。3.体模研究:用组织体模验证所提出的成像系统。4.活体研究:首先,对少量的人体乳房进行成像,以微调成像系统。其次,对人体乳房进行图像处理,并进行回溯统计分析。第三,对人体乳房进行成像,并对成像系统进行前瞻性验证。与公共卫生的相关性:成像技术使生物医学中的许多发现成为可能,并提供了疾病的早期诊断。功能成像不仅可以检测组织结构,还可以检测组织功能,这将对生物医学产生更大的影响。所提出的热声和光声成像技术可能为乳房新辅助治疗(化疗或激素治疗)的早期功能监测提供一种临床工具。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Barbara Monsees其他文献

Barbara Monsees的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Barbara Monsees', 18)}}的其他基金

Monitoring of Breast Neoadjuvant Therapy by Thermo- and Photo- Acoustic Tomograph
通过热声和光声断层扫描监测乳腺新辅助治疗
  • 批准号:
    8461471
  • 财政年份:
    2009
  • 资助金额:
    $ 57.74万
  • 项目类别:
Monitoring of Breast Neoadjuvant Therapy by Thermo- and Photo- Acoustic Tomograph
通过热声和光声断层扫描监测乳腺新辅助治疗
  • 批准号:
    7647824
  • 财政年份:
    2009
  • 资助金额:
    $ 57.74万
  • 项目类别:
Monitoring of Breast Neoadjuvant Therapy by Thermo- and Photo- Acoustic Tomograph
通过热声和光声断层扫描监测乳腺新辅助治疗
  • 批准号:
    8230594
  • 财政年份:
    2009
  • 资助金额:
    $ 57.74万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 57.74万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 57.74万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 57.74万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 57.74万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 57.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 57.74万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 57.74万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 57.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 57.74万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 57.74万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了